e not limited to, changing market
conditions, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products
and pricing, new product development, uncertainties related to the
regulatory approval process, and other risks detailed from time to time in
the Company's ongoing quarterly and annual reporting.
Bioniche Life Sciences Inc.
Amalgamated under the laws of Ontario
CONSOLIDATED BALANCE SHEETS
(Unaudited)
As at As at
September 30, June 30,
2007 2007
$ $
-------------------------------------------------------------------------
ASSETS
Current
Cash and cash equivalents 8,004,353 1,523,597
Short-term investments - 9,500,000
Accounts receivable 5,137,800 5,495,836
Inventories 5,486,543 5,480,167
Prepaid expenses and deposits 554,160 658,867
Foreign currency embedded derivatives 231,579 -
-------------------------------------------------------------------------
19,414,435 22,658,467
-------------------------------------------------------------------------
Long-term
Property, plant and equipment 9,513,696 9,557,359
Intangible assets 8,331,086 8,545,215
Goodwill 456,155 456,155
Deferred financing fees
'/>"/>
SOURCE Bioniche Life Sciences Inc. Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 Related medicine news :1.
Bioniche Responds to Australian Equine Influenza Outbreak2.
Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine3.
Bioniche Food Safety Vaccine Receives Global Top Honours in Industry Excellence Awards4.
Bioniche Receives Comment from USDA on a Field Trial for E. coli O157:H7 Cattle Vaccine5.
Media Advisory - Bioniche Discusses USDA Comment on E. coli O157:H7 Cattle Vaccine Field Trial6.
Bioniche to Present at Rodman & Renshaw 9th Annual Healthcare Conference7.
New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites8.
Haemacure Reports Third Quarter 2007 Results9.
First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion10.
Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best11.
MDS Reports Third Quarter 2007 Results